SOPHiA GENETICS Appoints Chief Medical Officer to Accelerate the Execution of Medical Strategy
SOPHiA GENETICS, leader in Data-Driven Medicine, announced today the appointment of Philippe Menu, MD-PhD, MBA, as Chief Medical Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005647/en/
Dr. Philippe Menu brings a unique blend of medical expertise across multiple areas including clinical medicine, fundamental research in molecular biology, and management consulting. He spent the last eight years at McKinsey & Company where he co-led the McKinsey Cancer Center and served dozens of clients in the biopharma sector. Dr. Menu advised global pharmaceutical companies, mid-size players and biotech alike across the entire value chain, with a major focus on innovative therapies and diagnostics in oncology and rare diseases.
“The potential linked to new-generation health data is limitless and it is our goal to continue expanding the scope of new clinical applications for our community of more than 1,000 hospitals across 82 countries,” affirmed Jurgi Camblong, CEO and Co-founder of SOPHiA GENETICS. "Philippe’s background and track record across different sectors of life sciences, including biopharma, will help the execution of new clinical-grade applications. In turn, this will allow the longitudinal monitoring of patients through multi-modal data approaches and the optimization of drug development.”
“It is a privilege to be joining SOPHiA GENETICS as Chief Medical Officer,” said Dr. Menu. “I am incredibly inspired by what the SOPHiA team has already achieved by analyzing half a million patients’ genomic profiles across the world through its unique and growing global network of hospital partners. Looking ahead, I am most impressed by the full potential to positively impact patients' lives that still lies ahead of us through the application of SOPHiA's multi-modal data approach. SOPHiA is uniquely positioned to help deliver transformative progress for patients around the world: we can help discover new biomarkers to develop new therapies, match the right treatment to the right patients in clinical trials as well as in routine clinical care, and follow patients longitudinally through a multi-omics approach to help predict who will most benefit from which therapies and why. I look forward to working closely with our hospital, biopharma and other healthcare ecosystem partners to help accelerate the adoption of Data-Driven Medicine."
About SOPHiA GENETICS
SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare diseases management, the universal SOPHiA Platform allows clinical researchers to act with precision and confidence. The company’s innovative approach enables an ever-expanding community of over 1’000 institutions to benefit from knowledge sharing, fostering a new era in healthcare. SOPHiA’s achievement is recognized by the MIT Technology Review’s "50 Smartest Companies". More info: SOPHiAGENETICS.COM , follow @SOPHiAGENETICS on Twitter.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-PERSONALIS18.2.2020 22:07:10 CET | Press release
Personalis, Inc. to Present at Biomarkers Series UK 2020 Conference
FRANCHISE-PARTNERS18.2.2020 22:02:10 CET | Press release
Franchise Partners Outlines Opportunities for Value Creation at Kirin Holdings
FL-PHILIP-STEIN18.2.2020 21:02:09 CET | Press release
Philip Stein Sleep Bracelet Clinically Proven To Improve Sleep and Overall Wellness, A Drug-Free Approach To Sleep Wellness
BERMUDA-BUSINESS-DEVLPMT18.2.2020 20:24:08 CET | Press release
Bermuda’s ‘White List’ Status Confirmed by the EU and Applauded by Industry
SUMITOMO-SHI-FW18.2.2020 18:14:15 CET | Press release
HELEN and Sumitomo SHI FW (SFW) Combine Forces: SFW CFB Boiler Technology to be Utilized at Vuosaari Bioenergy Plant
CAYMAN-GOVT-EFFORTS18.2.2020 17:12:04 CET | Press release
Cayman Finance Supports Government’s Efforts to Be Delisted by the European Union
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom